A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension

Withdrawn before enrolling · Phase 2

Conditions studied: Hypertension

In brief

To define the relationship between Cardene I.V. dose, serum concentrations, and blood pressure reduction in pediatric subjects with hypertension.

Key facts

Study ID

NCT00528827

Run by

Facet Biotech

People needed

0

Starts

2007-09-01

Expected to finish

2008-12-01

Last updated by the study team

2012-03-16

Who can join

Age: 2 and older, up to 16. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Evidence of Stage 1 or Stage 2 systolic hypertension at the time of screening.
• Male or female subjects, ages ≥2 to ≤16 years.
• Females who meet either of the following criteria:
• Non-childbearing potential , as documented by:
• a medical history of non-menstruation or
• surgical sterility from oophorectomy and/or hysterectomy. * A history of tubal ligation or evidence of a sterile sexual partner is insufficient evidence of non-childbearing potential.
• Childbearing potential: provide a negative urine pregnancy test within 24 hours of administration of study drug and agree to utilize effective contraception or remain abstinent during the entire treatment and follow-up periods of the study.
• Signed informed consent provided by an authorized subject representative and assent from subject, if feasible (based on local Institutional Review Board (IRB)/ethics panel requirements).

You may not qualify if…

• Subjects with seizures, altered state of consciousness, chest pain, facial palsy or intracranial hemorrhage at the time of screening.
• Receiving antihypertensive medication within a duration specified prior to screening.
• Treatment with cimetidine within 10 hours prior to dosing with study drug.
• Any known or suspected allergy to nicardipine hydrochloride.
• A calculated Glomerular Filtration Rate (GFR) under 30 mL/min/ 1.73 m2 as calculated using the Schwartz formula and the associated K values.
• Known history of severe aortic stenosis.
• Known history of severe left ventricular dysfunction.
• Known history of severely impaired hepatic function with portal hypertension.
• Liver function test (AST or ALT) results greater than or equal to twice the upper limit of normal.
• Receiving maintenance hemodialysis at screening or anticipated to require hemodialysis within 12 hours following initiation of treatment with study drug.
• Receiving a blood transfusion at screening or anticipated to require blood transfusions within 12 hours following initiation of treatment with study drug.
• Lack of appropriate intravenous (I.V.) access.
• Inability to tolerate a large-volume I.V. infusion.
• Any other condition or prior therapy, which, in the opinion of the investigator, would make the subject unsuitable for this study.
• Participation in any phase of another clinical research study involving the evaluation of another investigational drug or device within 30 days before randomization.

Where it is running

• Study site — Beverly Hills, California, United States
• Study site — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.